Moody’s downgrades Senegal to Caa1 amid rising debt concerns
CAMBRIDGE, Mass. - Editas Medicine, Inc. (NASDAQ:EDIT), whose stock has surged over 280% in the past six months and is trading near its 52-week high of $4.05, will deliver an oral presentation on its LDL-cholesterol lowering gene editing research at the European Society of Gene and Cell Therapy Congress in Seville, Spain, according to a press release statement.
The presentation, scheduled for Thursday, October 9, will highlight the company’s CRISPR gene editing approach that functionally upregulates LDLR in mice and non-human primates. Linda Burkly, Executive Vice President and Chief Scientific Officer at Editas, will present the research findings. According to InvestingPro data, while the company maintains strong liquidity with a current ratio of 2.77, it faces challenges with significant cash burn and negative profit margins.
The gene editing company is also participating in two investor conferences this month. Management will join a fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference on October 14 and participate in a panel discussion on genome editing technologies at the Chardan 9th Annual Genetic Medicines Conference on October 21 in New York.
Editas Medicine focuses on developing CRISPR genome editing systems into medicines for serious diseases. The company holds exclusive licenses to Cas12a and Cas9 patent estates from the Broad Institute, Harvard University, and other institutions for human medicine applications.
The presentation abstracts are available to registered attendees on the ESGCT website, and the company plans to post the presentation on its corporate website.
In other recent news, Editas Medicine has been the focus of several analyst updates and developments. H.C. Wainwright reiterated its Buy rating for Editas Medicine, setting a price target of $5.00, following the company’s nomination of EDIT-401 as its lead in vivo program. This CRISPR candidate has shown promising preclinical results, with significant reductions in LDL-C levels. Similarly, Wells Fargo raised its price target for Editas to $4.00, maintaining an Equal Weight rating, citing positive preclinical data for EDIT-401, which demonstrated substantial LDL-C reductions without adverse clinical observations.
Additionally, H.C. Wainwright increased its price target from $3.00 to $5.00, acknowledging Editas’ progress in its pipeline, particularly the selection of its first in vivo lead candidate expected by September 2025. Baird also raised its price target to $6.00, maintaining an Outperform rating, after reviewing Editas Medicine’s second-quarter 2025 earnings and pipeline updates. These developments reflect growing confidence in Editas Medicine’s ongoing research and potential future advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.